Longmont Small Business Launches Revolutionary AI Product
Summary
ParticleSentryᴬᴵ uses a convolutional neural network and computational statistics to analyze images produced by various microscopy platforms and creates a ‘fingerprint’ of the aggregate profile of a biologic drug. Our approach is exceptionally efficient because it learns to identify the optimum protein aggregate particles, and then sounds the alarm when statistically significant outliers are detected. This approach allows biologics manufacturers a method to quantify drug products for batch-to-batch consistency and still watch for outlier conditions,” said Glenn Brandon, CEO of the company. Until then, SentrySciences can develop fingerprints and collaborate on analysis and interpretation; this is easily facilitated remotely with an encrypted exchange of images. The company’s ParticleSentryAI system is the first artificial intelligence software platform for managing protein drug quality from creation to patient.